
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis

Biosimilars: Still Waiting for Promise to Materialize

Biosimilar SB2 May Work as Well as Infliximab for Rheumatoid Arthritis
Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
Biosimilars Great Debate: To Switch or Not?
